Sharps Compliance (SMED) Reports In-Line Q2 EPS

Sharps Compliance (NASDAQ: SMED) reported Q2 EPS of $0.07, in-line with the analyst estimate of $0.07. Revenue for the quarter came in at $18.9 million versus the consensus estimate of $17.99 million.

For earnings history and earnings-related data on Sharps Compliance (SMED) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c